{"Abbreviation":"","Aliases":["Clorazepic acid","Chlorazepate","Cchlorazepic acid","149128-44-9","7-Chloro-2,3-dihydro-2,2-dihydroxy-5-phenyl-1H-1,4-benzodiazepine-3-carboxylic acid","HSDB 3041","EINECS 245-926-8","4306-CB FREE ACID","ABBOTT-35616 FREE ACID","7-chloro-2-oxo-5-phenyl-2,3-dihydro-1H-1,4-benzodiazepine-3-carboxylic acid"],"Biological Half-Life":"The serum half-life of clorazepate is approximately 2 days. Nordiazepam, the primary metabolite, quickly appears in the blood and is eliminated from the plasma with an apparent half-life of about 40 to 50 hours.","CAS":"23887-31-2","CanonicalSMILES":"C1=CC=C(C=C1)C2=NC(C(=O)NC3=C2C=C(C=C3)Cl)C(=O)O","ChEBI":"CHEBI:3761","ChEMBL":"CHEMBL1213252","ChemicalClasses":["benzodiazepine"],"Color/Form":"FINE, LIGHT-YELLOW CRYSTALLINE POWDER; AQ SOLN ARE CLEAR, LIGHT-YELLOW","Dosing Info":[],"Drug Classes":"Breast Feeding; Lactation; Milk, Human; Hypnotics and Sedatives; Anti-Anxiety Agents; Benzodiazepines","Drug Indication":"Clorazepate is indicated for the management of anxiety disorders or the short-term relief of the symptoms of anxiety. It is also used as adjunctive therapy in the management of partial seizures and for the symptomatic relief of acute alcohol withdrawal.","Drug Warnings":"THIS DRUG SHOULD NOT BE DISCONTINUED ABRUPTLY, ALTHOUGH NO SERIOUS ADVERSE EFFECTS WERE OBSERVED UPON ABRUPT DISCONTINUATION OF 6 WK COURSE OF 120 MG DAILY. LONG-TERM THERAPY WITH LARGER THAN USUAL DOSES MAY RESULT IN PSYCHIC \u0026 PHYSICAL DEPENDENCE. /CLORAZEPATE DIPOTASSIUM SALT/","DrugClasses":["opioid","depressant"],"European Community (EC) Number":"245-926-8","FDA Pharmacological Classification":"D51WO0G0L4","Human Drugs":"Breast Feeding; Lactation; Milk, Human; Hypnotics and Sedatives; Anti-Anxiety Agents; Benzodiazepines","IUPACName":"7-chloro-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine-3-carboxylic acid","InChI":"InChI=1S/C16H11ClN2O3/c17-10-6-7-12-11(8-10)13(9-4-2-1-3-5-9)19-14(16(21)22)15(20)18-12/h1-8,14H,(H,18,20)(H,21,22)","InChIKey":"XDDJGVMJFWAHJX-UHFFFAOYSA-N","MeSH Pharmacological Classification":"Drugs used to prevent SEIZURES or reduce their severity. (See all compounds classified as Anticonvulsants.)","Melting Point":"228-235°C","MolecularFormula":"C\u003csub\u003e16\u003c/sub\u003eH\u003csub\u003e11\u003c/sub\u003eClN\u003csub\u003e2\u003c/sub\u003eO\u003csub\u003e3\u003c/sub\u003e","MolecularWeight":"314.72 g/mol","Pharmacodynamics":"Pharmacologically, clorazepate has the characteristics of benzodiazepines. Studies in healthy men have shown that clorazepate has depressant effects on the central nervous system. Since orally administered clorazepate dipotassium is rapidly decarboxylated to form nordiazepam, there is essentially no circulating parent drug. The use of benzodiazepines, including clorazepate, exposes users to abuse, misuse, and addiction risks, which can lead to overdose and death. Patients treated with clorazepate may also develop suicidal behavior and ideation, and the use of clorazepate may cause interference with psychomotor performance. The concomitant use of clorazepate with opioids may result in profound sedation, respiratory depression, coma, and death.","Physical Description":"Solid","PubChemId":2809,"Record Description":["Clorazepic acid is a 1,4-benzodiazepinone in which the oxo group is at position 2, and which is substituted at positions 3, 5, and 7 by carboxy, phenyl and chloro groups, respectively. It has a role as a prodrug, an anticonvulsant, an anxiolytic drug and a GABA modulator. It is a conjugate acid of a clorazepic acid anion.","Clorazepate is a DEA Schedule IV controlled substance. Substances in the DEA Schedule IV have a low potential for abuse relative to substances in Schedule III. It is a Depressants substance.","Clorazepic acid (clorazepate) is a water-soluble benzodiazepine with muscle-relaxant and anticonvulsant actions effective in the treatment of anxiety. Following administration, clorazepate is rapidly converted to nordiazepam (N-desmethyldiazepam), its active metabolite, before entering systemic circulation. Similar to other benzodiazepines, the active metabolite of clorazepate enhances the binding of gamma-aminobutyric acid (GABA) to the GABA type A (GABA-A) receptor, which promotes channel opening and neuronal hyperpolarization. The concomitant use of clorazepate and opioids may result in profound sedation, respiratory depression, coma, and death. Also, the use of clorazepate exposes users to users to the risks of abuse, misuse, and addiction, and its continued use may lead to significant physical dependence. In September 2020, a black box warning describing these risks was included on the product label of benzodiazepines as per FDA regulation. Clorazepate and its active metabolite, nordiazepam, are present in breast milk.","Clorazepic acid is a Benzodiazepine.","Clorazepate is a benzodiazepine used as an anticonvulsant as adjunctive therapy in management of epilepsy and as an anxiolytic for therapy of anxiety and alcohol withdrawal. Therapy with clorazepate is not associated with serum aminotransferase elevations, and cases of clinically apparent liver injury from clorazepate have been reported but are very rare.","CLORAZEPIC ACID is a small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1972 and is indicated for seizure and anxiety disorder and has 1 investigational indication. This drug has a black box warning from the FDA.","Clorazepate is only found in individuals that have used or taken this drug. It is a water-soluble benzodiazepine derivative effective in the treatment of anxiety. It has also muscle relaxant and anticonvulsant actions. [PubChem]Benzodiazepines bind nonspecifically to benzodiazepine receptors BNZ1, which mediates sleep, and BNZ2, which affects affects muscle relaxation, anticonvulsant activity, motor coordination, and memory. As benzodiazepine receptors are thought to be coupled to gamma-aminobutyric acid-A (GABA\u003csub\u003eA\u003c/sub\u003e) receptors, this enhances the effects of GABA by increasing GABA affinity for the GABA receptor. Binding of the inhibitory neurotransmitter GABA to the site opens the chloride channel, resulting in a hyperpolarized cell membrane that prevents further excitation of the cell.","A water-soluble benzodiazepine derivative effective in the treatment of anxiety. It has also muscle relaxant and anticonvulsant actions.","See also: Clorazepate Dipotassium (has salt form); Clorazepate Monopotassium (is active moiety of).","Clorazepic acid is a 1,4-benzodiazepinone in which the oxo group is at position 2, and which is substituted at positions 3, 5, and 7 by carboxy, phenyl and chloro groups, respectively. It has a role as a prodrug, an anticonvulsant, an anxiolytic drug and a GABA modulator. It is a conjugate acid of a clorazepic acid anion."],"References":[{"name":"Wikipedia","url":"https://en.wikipedia.org/wiki/Clorazepate"},{"name":"Wikidata","url":"https://www.wikidata.org/wiki/Q418850"},{"name":"DrugBank","url":"https://go.drugbank.com/drugs/DB00628"},{"name":"PubChem","url":"https://pubchem.ncbi.nlm.nih.gov/compound/2809"},{"name":"ChemSpider","url":"https://www.chemspider.com/Chemical-Structure.26331670.html"},{"name":"ChEMBL","url":"https://www.ebi.ac.uk/chembl/explore/compound/CHEMBL1213252"},{"name":"ChEBI","url":"https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:3761"},{"name":"Common Chemistry","url":"https://commonchemistry.cas.org/detail?cas_rn=23887-31-2"},{"name":"HMDB","url":"https://hmdb.ca/metabolites/HMDB0014766"},{"name":"KEGG","url":"https://www.kegg.jp/entry/C06921"},{"name":"UNII","url":"https://gsrs.ncats.nih.gov/ginas/app/ui/substances/D51WO0G0L4"},{"name":"EPA DSSTox","url":"https://comptox.epa.gov/dashboard/chemical/details/DTXSID20863674"}],"Solubility":"Very soluble","Stability/Shelf Life":"AQ SOLN ARE UNSTABLE. /CLORAZEPATE DIPOTASSIUM SALT/","StructureBase64":"<svg xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" height="91.494mm" version="1.2" viewBox="0 0 108.285 91.494" width="108.285mm">
      
    <desc>Generated by the Chemistry Development Kit (http://github.com/cdk)</desc>
      
    <g fill="#FF0D0D" stroke="#000000" stroke-linecap="round" stroke-linejoin="round" stroke-width=".7">
            
        <rect fill="#FFFFFF" height="92.0" stroke="none" width="109.0" x=".0" y=".0"/>
            
        <g class="mol" id="mol1">
                  
            <g class="bond" id="mol1bnd1">
                        
                <line x1="46.705" x2="61.276" y1="90.439" y2="85.943"/>
                        
                <line x1="47.331" x2="59.211" y1="87.694" y2="84.029"/>
                      
            </g>
                  
            <line class="bond" id="mol1bnd2" x1="61.276" x2="64.662" y1="85.943" y2="71.084"/>
                  
            <g class="bond" id="mol1bnd3">
                        
                <line x1="64.662" x2="53.476" y1="71.084" y2="60.721"/>
                        
                <line x1="61.971" x2="52.851" y1="71.916" y2="63.465"/>
                      
            </g>
                  
            <line class="bond" id="mol1bnd4" x1="53.476" x2="38.906" y1="60.721" y2="65.216"/>
                  
            <g class="bond" id="mol1bnd5">
                        
                <line x1="38.906" x2="35.52" y1="65.216" y2="80.075"/>
                        
                <line x1="40.97" x2="38.21" y1="67.131" y2="79.244"/>
                      
            </g>
                  
            <line class="bond" id="mol1bnd6" x1="46.705" x2="35.52" y1="90.439" y2="80.075"/>
                  
            <line class="bond" id="mol1bnd7" x1="53.476" x2="56.862" y1="60.721" y2="45.861"/>
                  
            <g class="bond" id="mol1bnd8">
                        
                <line x1="56.862" x2="68.391" y1="45.861" y2="43.176"/>
                        
                <line x1="57.464" x2="67.838" y1="43.217" y2="40.802"/>
                      
                <line class="hi" stroke="#3050F8" x1="68.391" x2="62.62650000000001" y1="43.176" y2="44.5185"/>
                <line class="hi" stroke="#3050F8" x1="67.838" x2="62.650999999999996" y1="40.802" y2="42.0095"/>
            </g>
                  
            <line class="bond" id="mol1bnd9" x1="73.482" x2="78.299" y1="38.696" y2="28.691"/>
                  
            <line class="bond" id="mol1bnd10" x1="78.299" x2="71.695" y1="28.691" y2="14.975"/>
                  
            <g class="bond" id="mol1bnd11">
                        
                <line x1="70.379" x2="77.799" y1="14.668" y2="5.406"/>
                        
                <line x1="72.282" x2="79.702" y1="16.193" y2="6.931"/>
                      
                <line class="hi" stroke="#FF0D0D" x1="77.799" x2="74.089" y1="5.405999999999999" y2="10.036999999999999"/>
                <line class="hi" stroke="#FF0D0D" x1="79.702" x2="75.99199999999999" y1="6.931000000000001" y2="11.562000000000001"/>
            </g>
                  
            <line class="bond" id="mol1bnd12" x1="71.695" x2="60.166" y1="14.975" y2="12.29"/>
                  
            <line class="bond" id="mol1bnd13" x1="53.83" x2="44.975" y1="13.957" y2="21.071"/>
                  
            <g class="bond" id="mol1bnd14">
                        
                <line x1="44.975" x2="44.975" y1="36.311" y2="21.071"/>
                        
                <line x1="42.536" x2="42.536" y1="34.903" y2="22.479"/>
                      
            </g>
                  
            <line class="bond" id="mol1bnd15" x1="56.862" x2="44.975" y1="45.861" y2="36.311"/>
                  
            <line class="bond" id="mol1bnd16" x1="44.975" x2="31.767" y1="36.311" y2="43.931"/>
                  
            <g class="bond" id="mol1bnd17">
                        
                <line x1="18.559" x2="31.767" y1="36.311" y2="43.931"/>
                        
                <line x1="20.997" x2="31.767" y1="34.903" y2="41.116"/>
                      
            </g>
                  
            <line class="bond" id="mol1bnd18" x1="18.559" x2="18.559" y1="36.311" y2="21.071"/>
                  
            <g class="bond" id="mol1bnd19">
                        
                <line x1="31.767" x2="18.559" y1="13.451" y2="21.071"/>
                        
                <line x1="31.767" x2="20.997" y1="16.266" y2="22.479"/>
                      
            </g>
                  
            <line class="bond" id="mol1bnd20" x1="44.975" x2="31.767" y1="21.071" y2="13.451"/>
                  
            <line class="bond" id="mol1bnd21" x1="18.559" x2="6.875" y1="36.311" y2="43.059"/>
                  
            <line class="bond" id="mol1bnd22" x1="78.299" x2="93.539" y1="28.691" y2="28.691"/>
                  
            <g class="bond" id="mol1bnd23">
                        
                <line x1="94.243" x2="100.245" y1="27.472" y2="37.868"/>
                        
                <line x1="92.132" x2="98.134" y1="28.691" y2="39.087"/>
                      
                <line class="hi" stroke="#FF0D0D" x1="100.245" x2="97.244" y1="37.868" y2="32.67"/>
                <line class="hi" stroke="#FF0D0D" x1="98.134" x2="95.13300000000001" y1="39.087" y2="33.889"/>
            </g>
                  
            <line class="bond" id="mol1bnd24" x1="93.539" x2="99.19" y1="28.691" y2="18.904"/>
                  
            <path class="atom" d="M73.636 44.857h-.72l-2.62 -4.066h-.029q.012 .238 .029 .595q.024 .357 .024 .732v2.739h-.565v-4.9h.714l2.607 4.054h.03q-.006 -.107 -.018 -.327q-.012 -.22 -.023 -.476q-.006 -.262 -.006 -.483v-2.768h.577v4.9z" fill="#3050F8" id="mol1atm8" stroke="none"/>
                  
            <path class="atom" d="M83.483 3.078q.0 .756 -.256 1.328q-.256 .565 -.756 .881q-.5 .315 -1.244 .315q-.756 .0 -1.262 -.315q-.506 -.316 -.756 -.887q-.244 -.572 -.244 -1.334q-.0 -.75 .244 -1.309q.25 -.566 .756 -.881q.506 -.316 1.274 -.316q.732 .0 1.232 .316q.5 .309 .756 .875q.256 .565 .256 1.327zM79.62 3.078q-.0 .923 .387 1.459q.392 .53 1.22 .53q.839 -.0 1.22 -.53q.387 -.536 .387 -1.459q.0 -.929 -.387 -1.452q-.381 -.524 -1.208 -.524q-.834 -.0 -1.226 .524q-.393 .523 -.393 1.452z" id="mol1atm11" stroke="none"/>
                  
            <g class="atom" id="mol1atm12">
                        
                <path d="M58.802 13.97h-.72l-2.619 -4.066h-.03q.012 .238 .03 .596q.024 .357 .024 .732v2.738h-.566v-4.899h.714l2.608 4.054h.03q-.006 -.107 -.018 -.327q-.012 -.221 -.024 -.477q-.006 -.262 -.006 -.482v-2.768h.577v4.899z" fill="#3050F8" stroke="none"/>
                        
                <path d="M58.666 8.509h-.62v-2.286h-2.512v2.286h-.613v-4.899h.613v2.071h2.512v-2.071h.62v4.899z" fill="#3050F8" stroke="none"/>
                      
            </g>
                  
            <path class="atom" d="M2.906 42.117q-.786 .0 -1.239 .53q-.452 .524 -.452 1.447q-.0 .911 .417 1.446q.422 .53 1.268 .53q.321 .0 .607 -.053q.291 -.06 .565 -.143v.536q-.274 .101 -.565 .148q-.292 .054 -.697 .054q-.744 -.0 -1.25 -.31q-.5 -.309 -.75 -.875q-.25 -.571 -.25 -1.339q.0 -.744 .268 -1.31q.274 -.565 .804 -.881q.529 -.321 1.279 -.321q.78 -.0 1.352 .285l-.244 .524q-.226 -.101 -.506 -.184q-.274 -.084 -.607 -.084zM5.662 46.541h-.601v-5.215h.601v5.215z" fill="#1FF01F" id="mol1atm19" stroke="none"/>
                  
            <path class="atom" d="M103.419 41.886q-.0 .756 -.256 1.328q-.256 .565 -.756 .881q-.501 .315 -1.245 .315q-.756 .0 -1.262 -.315q-.506 -.316 -.756 -.887q-.244 -.572 -.244 -1.334q.0 -.75 .244 -1.309q.25 -.566 .756 -.881q.506 -.316 1.274 -.316q.732 .0 1.233 .316q.5 .309 .756 .875q.256 .565 .256 1.327zM99.555 41.886q-.0 .923 .387 1.459q.393 .53 1.22 .53q.84 -.0 1.221 -.53q.387 -.536 .387 -1.459q-.0 -.928 -.387 -1.452q-.381 -.524 -1.209 -.524q-.833 -.0 -1.226 .524q-.393 .524 -.393 1.452z" id="mol1atm21" stroke="none"/>
                  
            <g class="atom" id="mol1atm22">
                        
                <path d="M103.419 15.49q-.0 .756 -.256 1.327q-.256 .566 -.756 .881q-.501 .316 -1.245 .316q-.756 -.0 -1.262 -.316q-.506 -.315 -.756 -.887q-.244 -.571 -.244 -1.333q.0 -.75 .244 -1.31q.25 -.565 .756 -.881q.506 -.315 1.274 -.315q.732 -.0 1.233 .315q.5 .31 .756 .875q.256 .566 .256 1.328zM99.555 15.49q-.0 .923 .387 1.458q.393 .53 1.22 .53q.84 .0 1.221 -.53q.387 -.535 .387 -1.458q-.0 -.929 -.387 -1.453q-.381 -.524 -1.209 -.524q-.833 .0 -1.226 .524q-.393 .524 -.393 1.453z" stroke="none"/>
                        
                <path d="M107.725 17.942h-.619v-2.286h-2.513v2.286h-.613v-4.899h.613v2.072h2.513v-2.072h.619v4.899z" stroke="none"/>
                      
            </g>
                
            <line class="hi" id="mol1bnd9" stroke="#3050F8" x1="73.482" x2="75.8905" y1="38.696" y2="33.6935"/>
            <line class="hi" id="mol1bnd12" stroke="#3050F8" x1="60.166" x2="65.9305" y1="12.29" y2="13.6325"/>
            <line class="hi" id="mol1bnd12" stroke="#3050F8" x1="60.166" x2="65.9305" y1="12.29" y2="13.6325"/>
            <line class="hi" id="mol1bnd13" stroke="#3050F8" x1="53.83" x2="49.4025" y1="13.957" y2="17.514000000000003"/>
            <line class="hi" id="mol1bnd13" stroke="#3050F8" x1="53.83" x2="49.4025" y1="13.957" y2="17.514000000000003"/>
            <line class="hi" id="mol1bnd21" stroke="#1FF01F" x1="6.875" x2="12.717" y1="43.059" y2="39.685"/>
            <line class="hi" id="mol1bnd24" stroke="#FF0D0D" x1="99.19" x2="96.36449999999999" y1="18.904" y2="23.7975"/>
        </g>
          
    </g>
    
</svg>
","Therapeutic Uses":"FOR SYMPTOMATIC RELIEF OF ANXIETY ASSOCIATED WITH NEUROSIS, PSYCHONEUROSES WITH SYMPTOMS OF ANXIETY, \u0026 AS ADJUNCT IN DISEASE STATES IN WHICH ANXIETY IS PROMINENT FEATURE. /DIPOTASSIUM SALT/","Title":"Clorazepate","UNII":"D51WO0G0L4","Wikidata":"Q418850","XLogP":3.3}